Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Phase 1
Completed
NCT04520659
| Condition | RSV Infection |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|
| Status | Completed |
|---|
| Enrollment | 81 participants |
|---|
| Interventions | RSV LID/ΔM2-2/1030s |
|---|
| Start date | Mar 16, 2022 |
|---|
| Completion date | Apr 18, 2024 |
|---|
| Results posted | Aug 22, 2025 |
|---|
Summary
The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of a recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine, LID/ΔM2-2/1030s, in RSV-seronegative infants and children 6 to 24 months of age.
Frequency of Grade 1 or Higher Solicited Adverse Events (AEs) by Grade
Measured through Day 28 · Participants
| Group 1: RSV LID/ΔM2-2/1030s | 14 Participants |
|---|
| Group 1: Placebo | 7 Participants |
|---|
| Group 2: RSV LID/ΔM2-2/1030s | 27 Participants |
|---|
| Group 2: Placebo | 11 Participants |
|---|
| Groups 1 and 2 Combined: RSV LID/ΔM2-2/1030s | 41 Participants |
|---|
| Groups 1 and 2 Combined: Placebo | 18 Participants |
|---|
Frequency of Grade 2 or Higher Lower Respiratory Infections (LRI) by Grade
Measured through Day 28 · Participants
| Group 1: RSV LID/ΔM2-2/1030s | 14 Participants |
|---|
| Group 1: Placebo | 7 Participants |
|---|
| Group 2: RSV LID/ΔM2-2/1030s | 39 Participants |
|---|
| Group 2: Placebo | 17 Participants |
|---|
| Groups 1 and 2 Combined: RSV LID/ΔM2-2/1030s | 53 Participants |
|---|
| Groups 1 and 2 Combined: Placebo | 24 Participants |
|---|
Number of Participants With Unsolicited Adverse Events (AEs) by Grade of Severity
Measured through Day 28 · Participants
| Group 1: RSV LID/ΔM2-2/1030s | 14 Participants |
|---|
| Group 1: Placebo | 6 Participants |
|---|
| Group 2: RSV LID/ΔM2-2/1030s | 29 Participants |
|---|
| Group 2: Placebo | 16 Participants |
|---|
| Groups 1 and 2 Combined: RSV LID/ΔM2-2/1030s | 43 Participants |
|---|
| Groups 1 and 2 Combined: Placebo | 22 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.